H. Neves and H. F. Kwok, Recent advances in the field of anti-cancer immunotherapy, BBA clinical, vol.3, pp.280-288, 2015.

A. M. Scott, J. D. Wolchok, and L. J. Old, Antibody therapy of cancer, Nat Rev Cancer, vol.12, pp.278-87, 2012.

. Hu-z, Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer Journal of Immune Based Therapies, Vaccines and Antimicrobials, vol.2, pp.1-8, 2013.

G. Cartron and H. Watier, Obinutuzumab: what is there to learn from clinical trials? Blood, 2017.

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, pp.754-762, 2002.

R. Jefferis, Glycosylation as a strategy to improve antibody-based therapeutics, Nat Rev Drug Discov, vol.8, pp.226-260, 2009.

M. Giuliani, B. Janji, and G. Berchem, Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression, Oncotarget, vol.8, pp.24031-24075, 2017.

D. N. Vo, A. C. Allende-vega, N. Morschhauser, F. Houot, R. Menard et al., NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment
URL : https://hal.archives-ouvertes.fr/hal-01780378

E. Krzywinska, N. Allende-vega, A. Cornillon, D. Vo, L. Cayrefourcq et al., Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers, EBioMedicine, vol.2, pp.1364-76, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01867114

E. Krzywinska, A. Cornillon, N. Allende-vega, D. N. Vo, R. C. Lu et al.,

, Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity, vol.11, p.150434, 2016.

M. Villalba, M. G. Rathore, N. Lopez-royuela, E. Krzywinska, J. Garaude et al., From tumor cell metabolism to tumor immune escape, Int J Biochem Cell Biol, vol.45, pp.106-119, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00726717

M. Villalba, N. Lopez-royuela, E. Krzywinska, M. G. Rathore, R. A. Hipskind et al., Chemical metabolic inhibitors for the treatment of blood-borne cancers. Anti-cancer agents in medicinal chemistry, vol.14, pp.223-255, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01867009

C. Baier, A. Fino, C. Sanchez, L. Farnault, P. Rihet et al., Natural Killer Cells Modulation in Hematological Malignancies, Frontiers in immunology, vol.4, p.459, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01455668

P. Ambrosini, F. Loiacono, R. Conte, L. Moretta, C. Vitale et al., IL-1beta inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood CD34(+) precursors, Eur J Immunol, vol.45, pp.2061-71, 2015.

L. Moretta, G. Pietra, P. Vacca, D. Pende, F. Moretta et al., Human NK cells: From surface receptors to clinical applications, Immunology letters, vol.178, pp.15-24, 2016.

A. Muntasell, M. C. Ochoa, L. Cordeiro, P. Berraondo, A. Lopez-diaz-de-cerio et al., Targeting NK-cell checkpoints for cancer immunotherapy, Curr Opin Immunol, vol.45, pp.73-81, 2017.

A. Sarvaria, D. Jawdat, J. A. Madrigal, and A. Saudemont, Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications, Frontiers in immunology, vol.8, p.329, 2017.

P. D. Kottaridis, J. North, M. Tsirogianni, C. Marden, E. R. Samuel et al., Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial, PLoS One, vol.10, p.123416, 2015.

M. J. Besser, T. Shoham, O. Harari-steinberg, N. Zabari, R. Ortenberg et al., Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies, PLoS One, vol.8, p.57922, 2013.

X. Deng, H. Terunuma, A. Terunuma, T. Takane, and M. Nieda, Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded gammadelta T cells or alphabeta T cells, International immunopharmacology, vol.22, pp.486-91, 2014.

C. J. Voskens, R. Watanabe, S. Rollins, D. Campana, K. Hasumi et al., Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity, Journal of experimental & clinical cancer research : CR, vol.29, p.134, 2010.

W. Wang, A. K. Erbe, J. A. Hank, Z. S. Morris, P. M. Sondel et al., NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy, Frontiers in immunology, vol.6, p.368, 2015.

N. Royuela, All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity, Int J Biochem Cell Biol, vol.49, pp.42-52, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01867016

D. Sanchez-martinez, G. Azaceta, A. Muntasell, N. Aguilo, D. Nunez et al., Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells, Oncoimmunology, vol.4, p.991613, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01835574

D. Sanchez-martinez, P. M. Lanuza, N. Gomez, A. Muntasell, E. Cisneros et al., Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells, Frontiers in immunology, vol.7, p.454, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01835596

D. Nunez, M. P. Domingo, D. Sánchez-martínez, V. Cebolla, A. Chiou et al., Recombinant production of human ICAM-1 chimeras by single step on column refolding and purification, Process in Biochemistry, vol.48, pp.708-723, 2013.

N. Allende-vega, E. Krzywinska, S. Orecchioni, N. Lopez-royuela, and F. Reggiani,

G. Talarico, The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism, Oncotarget, vol.6, pp.19228-19273, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01868552

J. I. Aguilo, J. Garaude, J. Pardo, M. Villalba, and A. Anel, Protein kinase C-theta is required for NK cell activation and in vivo control of tumor progression, J Immunol, vol.182, pp.1972-81, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02194087

A. Anel, J. I. Aguilo, E. Catalan, J. Garaude, M. G. Rathore et al., Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity, Frontiers in immunology, vol.3, p.187, 2012.

L. C. Ndhlovu, S. Lopez-verges, J. D. Barbour, R. B. Jones, A. R. Jha et al., Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity, Blood, vol.119, pp.3734-3777, 2012.

D. M. Benson, C. E. Bakan, A. Mishra, C. C. Hofmeister, Y. Efebera et al.,

, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, Blood, vol.116, pp.2286-94, 2010.

M. Luetke-eversloh, M. Killig, C. Romagnani, C. M. Nielsen, M. J. White et al., Signatures of human NK cell development and terminal differentiation, Frontiers in immunology, vol.4, p.57, 2013.

, Expression on Human NK Cells and Relevance to Disease, Frontiers in immunology, vol.4, p.422, 2013.

S. Trivedi, R. M. Srivastava, F. Concha-benavente, S. Ferrone, T. M. Garcia-bates et al., Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients, Clin Cancer Res, vol.22, pp.5229-5266, 2016.

S. S. Evans and A. B. Clemmons, Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia, Journal of the advanced practitioner in oncology, vol.6, pp.370-374, 2015.

Y. Zhu, B. Huang, J. Shi, D. F. Barber, M. Faure et al., Fas ligand and lytic granule differentially control cytotoxic dynamics of Natural Killer cell against cancer target, Oncotarget, vol.37, pp.3653-3662, 2004.

R. M. Shallis, C. M. Terry, and S. H. Lim, The multi-faceted potential of CD38 antibody targeting in multiple myeloma, Cancer Immunol Immunother, 2017.

J. P. Veluchamy, A. M. Heeren, J. Spanholtz, J. D. Van-eendenburg, D. A. Heideman et al., High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status, Cancer Immunol Immunother, vol.66, pp.51-61, 2017.

R. Beroukhim, C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri et al., The landscape of somatic copy-number alteration across human cancers, Nature, vol.463, pp.899-905, 2010.

D. De-miguel, G. Basanez, D. Sanchez, P. G. Malo, I. Marzo et al., Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells, Molecular pharmaceutics, vol.10, pp.893-904, 2013.

M. Balsamo, W. Vermi, M. Parodi, G. Pietra, C. Manzini et al., Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor, Eur J Immunol, vol.42, pp.1833-1875, 2012.

P. Carrega, B. Morandi, R. Costa, G. Frumento, G. Forte et al., Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells, Cancer, vol.112, pp.863-75, 2008.

N. Halama, M. Braun, C. Kahlert, A. Spille, C. Quack et al., Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, Clin Cancer Res, vol.17, pp.678-89, 2011.

M. R. Parkhurst, J. P. Riley, M. E. Dudley, and S. A. Rosenberg, Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression, Clin Cancer Res, vol.17, pp.6287-97, 2011.

S. M. Federico, M. B. Mccarville, B. L. Shulkin, P. M. Sondel, J. A. Hank et al., A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma, Clin Cancer Res, 2017.

A. C. Talleur, B. M. Triplett, S. Federico, E. Mamcarz, W. Janssen et al., Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells, Biol Blood Marrow Transplant, 2017.

M. Shevtsov and G. Multhoff, Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies, Frontiers in immunology, vol.7, p.492, 2016.

V. Bachanova, L. J. Burns, D. H. Mckenna, J. Curtsinger, and A. Panoskaltsis-mortari,

B. R. Lindgren, Allogeneic natural killer cells for refractory lymphoma, Cancer Immunol Immunother, vol.59, pp.1739-1783, 2010.

C. A. Ramos, B. Savoldo, and G. Dotti, CD19-CAR trials, Cancer journal, vol.20, pp.112-120, 2014.

E. Ullrich, E. Salzmann-manrique, S. Bakhtiar, M. Bremm, S. Gerstner et al., Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation, Frontiers in immunology, vol.7, p.595, 2016.

N. N. Shah, K. Baird, C. P. Delbrook, T. A. Fleisher, M. E. Kohler et al., Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation, Blood, vol.125, pp.784-92, 2015.

N. Vey, J. H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet et al., A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, pp.4317-4340, 2012.

M. Carlsten, N. Korde, R. Kotecha, R. Reger, S. Bor et al., Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma, Clin Cancer Res, vol.22, pp.5211-5233, 2016.

K. Lagrue, A. Carisey, D. J. Morgan, R. Chopra, and D. M. Davis, Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, vol.126, pp.50-60, 2015.